Investor Area

Array
(
    [0] => https:
    [1] => 
    [2] => www.clinuvel.com
    [3] => investors
    [4] => news
)
Home / Investors / News

News

13 March 2016   ** Not for release or distribution in the United States ** CLINUVEL Pharmaceuticals Limited has successfully raised A$8.3 million dollars via a private placement (“Placement”) to existing and new international institutional and professional investors.   Download PDF for more

Download PDF
 
Friday, 11 March 2016

Request for Trading Halt

11 March 2016   Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV) requests a trading halt with respect to its ordinary shares from the commencement of trading on Friday 11th March 2016 until the commencement of trading Tuesday 15th March, 2016.   Download PDF for more

Download PDF
 
Friday, 19 February 2016

Appendix 4D and Half Year Report

19 February 2016   Your Directors present their report on the company and its controlled entities for the half year ended 31 December 2015.   Download PDF for more

Download PDF
 

19 February 2016   CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the commercialisation of its novel drug SCENESSE® (afamelanotide 16mg) in adult patients with erythropoietic protoporphyria (EPP) in Europe. CLINUVEL has been working towards finalising distribution infrastructure, with a focus on a Risk Management Plan (RMP) and pharmacovigilance […]

Download PDF
 

  10 February 2016   Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its lead drug SCENESSE® (afamelanotide 16mg) has received an additional orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of cutaneous variants of porphyria. The ODD recognises the potential of afamelanotide to […]

Download PDF
 

8 February 2016   Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY) presented to an international porphyria  patient meeting, held in Rotterdam, the Netherlands, on February 6, 2016. The presentation and speaking notes are  appended to this announcement.   Download PDF for more

Download PDF
 
Thursday, 28 January 2016

Appendix 4C – Q2 FY16

28 January 2016   Enclosed is a copy of the Quarterly report for entities admitted on the basis of commitments.     Download PDF for more

Download PDF
 
Monday, 25 January 2016

Form 604

25 January 2016   Enclosed is a notice of a change of interest in substantial holder.   Download PDF for more

Download PDF
 
Wednesday, 20 January 2016

CEO Brief – January 20, 2016

20 January 2016   Having both received and provided services within the healthcare sector over the years I am all too aware of the peril of compromised health and loss of your livelihood. In Clinuvel’s case we aspire to make our patients realise their dreams and ambitions by making SCENESSE® (afamelanotide 16mg) available to all […]

Download PDF
 
Monday, 18 January 2016

Form 604

18 January 2016   Enclosed is a notice of change of interests of a substantial holder.    Download PDF for more

Download PDF